BR112016022844A2 - método para aperfeiçoar a solubilidade de proteínas e peptídeos utilizando-se uma ligação de fragmento fc de imunoglobulinas - Google Patents

método para aperfeiçoar a solubilidade de proteínas e peptídeos utilizando-se uma ligação de fragmento fc de imunoglobulinas

Info

Publication number
BR112016022844A2
BR112016022844A2 BR112016022844A BR112016022844A BR112016022844A2 BR 112016022844 A2 BR112016022844 A2 BR 112016022844A2 BR 112016022844 A BR112016022844 A BR 112016022844A BR 112016022844 A BR112016022844 A BR 112016022844A BR 112016022844 A2 BR112016022844 A2 BR 112016022844A2
Authority
BR
Brazil
Prior art keywords
immunoglobulin
peptide
fragment
solubility
protein
Prior art date
Application number
BR112016022844A
Other languages
English (en)
Inventor
Jin Kim Dae
Kyu Lim Hyung
Soo Lee Jong
Chang Kwon Se
Min Bae Sung
Youb Jung Sung
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR112016022844A2 publication Critical patent/BR112016022844A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

resumo ?método para aperfeiçoar a solubilidade de proteínas e peptídeos utilizando-se uma ligação de fragmento fc de imunoglobulinas? a presente invenção refere-se a um método para aperfeiçoar a solubilidade de uma proteína ou peptídeo fisiologicamente ativos comparada àquela de uma pro-teína ou peptídeo fisiologicamente ativos que não é conjugada a um fragmento fc de imunoglobulinas, em que o método compreende conjugar a proteína ou peptídeo fisiologicamente ativos a um fragmento fc de imunoglobulinas; e a uma composi-ção para aperfeiçoar a solubilidade de uma proteína ou peptídeo fisiologicamente ativos, que compreende um fragmento fc de imunoglobulinas, em que a composi-ção aperfeiçoa a solubilidade comparada a uma composição sem um fragmento fc de imunoglobulinas.
BR112016022844A 2014-03-31 2015-03-31 método para aperfeiçoar a solubilidade de proteínas e peptídeos utilizando-se uma ligação de fragmento fc de imunoglobulinas BR112016022844A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140038032 2014-03-31
PCT/KR2015/003195 WO2015152618A1 (ko) 2014-03-31 2015-03-31 면역글로불린 fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법

Publications (1)

Publication Number Publication Date
BR112016022844A2 true BR112016022844A2 (pt) 2017-10-17

Family

ID=54240858

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016022844A BR112016022844A2 (pt) 2014-03-31 2015-03-31 método para aperfeiçoar a solubilidade de proteínas e peptídeos utilizando-se uma ligação de fragmento fc de imunoglobulinas

Country Status (23)

Country Link
US (2) US20170128589A1 (pt)
EP (2) EP3889185A3 (pt)
JP (3) JP2017511335A (pt)
KR (2) KR102385120B1 (pt)
CN (2) CN106488933A (pt)
AU (1) AU2015242657B2 (pt)
BR (1) BR112016022844A2 (pt)
CA (1) CA2944138C (pt)
DK (1) DK3127923T3 (pt)
EA (1) EA201691795A1 (pt)
ES (1) ES2897935T3 (pt)
HU (1) HU231358B1 (pt)
IL (1) IL248111B (pt)
MX (1) MX2016012788A (pt)
MY (1) MY192248A (pt)
NO (1) NO20161667A1 (pt)
NZ (1) NZ724926A (pt)
PH (1) PH12016501937A1 (pt)
PL (1) PL3127923T3 (pt)
SG (2) SG10202107752PA (pt)
UA (1) UA124182C2 (pt)
WO (1) WO2015152618A1 (pt)
ZA (1) ZA201607344B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3127923T3 (da) * 2014-03-31 2021-11-22 Hanmi Pharm Ind Co Ltd Fremgangsmåde til forbedring af oppløselighed af protein og peptid ved hjælp af immunoglobulin-fc-fragment-binding
CN109069569B (zh) * 2015-12-02 2023-02-14 韩美药品株式会社 使用脂肪酸衍生物的蛋白缀合物及其制备方法
KR102645064B1 (ko) * 2017-02-03 2024-03-08 한미약품 주식회사 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
CN106892978A (zh) * 2017-04-18 2017-06-27 天津世传生物科技有限公司 复合物、蛋白质及二者的制备方法
EP3641782A4 (en) * 2017-06-20 2021-03-24 Madrigal Pharmaceuticals, Inc. COMBINED THERAPIES INCLUDING TARGETED THERAPEUTICS
KR102053009B1 (ko) * 2018-09-19 2019-12-09 주식회사 바이오앱 돼지 열병 백신용 조성물 및 이의 제조 방법
WO2020101187A1 (ko) 2018-11-15 2020-05-22 주식회사 바이오앱 식물체에서 바이러스-유사 입자를 발현하는 재조합 벡터 및 이를 이용한 써코바이러스-유사 입자를 포함하는 백신 조성물의 제조방법
KR102250576B1 (ko) 2018-11-15 2021-05-12 주식회사 바이오앱 식물 발현 시스템에서 캡시드 단백질의 발현을 증가시키는 재조합 벡터 및 이를 이용한 바이러스-유사 입자의 제조방법
KR102288367B1 (ko) 2018-11-15 2021-08-11 주식회사 바이오앱 식물체에서 바이러스-유사 입자를 발현하는 재조합 벡터 및 이를 이용한 써코바이러스-유사 입자를 포함하는 백신 조성물의 제조방법
US20200262887A1 (en) 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
PE20220401A1 (es) * 2019-09-06 2022-03-22 Novartis Ag Proteinas de fusion terapeuticas
KR102450007B1 (ko) * 2020-10-16 2022-10-04 주식회사 아이엠바이오로직스 IgM 영역을 이용한 융합단백질 플랫폼
KR20220122815A (ko) 2021-02-25 2022-09-05 주식회사 바이오앱 식물 발현 시스템을 이용한 알팔파 모자이크 바이러스 유사 입자 제조 방법 및 이의 활용
KR20240027904A (ko) 2022-08-22 2024-03-05 (주) 에빅스젠 용해도 개선용 펩티드 및 이를 포함하는 용해도 개선 조성물

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
SI1724284T1 (sl) * 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
UA87458C2 (ru) * 2003-06-12 2009-07-27 Елі Ліллі Енд Компані Гибридные белки-аналоги glp-1
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
ATE555133T1 (de) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
PL1831252T3 (pl) * 2004-12-22 2009-11-30 Lilly Co Eli Preparaty białka fuzyjnego analogu GLP-1
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
KR100755315B1 (ko) 2005-04-11 2007-09-05 엘지전자 주식회사 멀티에어컨 시스템 및 그 동작 방법
GB2427360A (en) * 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CA2658673A1 (en) * 2005-07-27 2008-02-01 Gerald J. Prud'homme Composition and method for prevention and treatment of type i and type ii diabetes
KR100824505B1 (ko) 2005-08-16 2008-04-22 한미약품 주식회사 개시 메티오닌 잔기가 제거된 면역글로불린 Ｆｃ 영역의대량 생산방법
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP2162472B1 (en) * 2007-05-30 2013-02-27 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
JPWO2009020094A1 (ja) * 2007-08-09 2010-11-04 第一三共株式会社 疎水性分子で修飾した抗体
JP2011511778A (ja) * 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
NZ590358A (en) * 2008-07-23 2012-04-27 Hanmi Holdings Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
CA2747490C (en) * 2008-12-19 2017-02-14 Indiana University Research And Technology Corporation Insulin analogs
CN102573920B (zh) * 2009-07-27 2015-01-14 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
CN102753147B (zh) * 2010-01-19 2017-10-31 韩美科学株式会社 长效红细胞生成素缀合物的液体制剂
CN102740840A (zh) * 2010-01-19 2012-10-17 韩美科学株式会社 长效g-csf缀合物的液体制剂
AR081755A1 (es) * 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
US9981017B2 (en) * 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AR080993A1 (es) * 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
KR101830344B1 (ko) * 2010-10-26 2018-02-22 한미사이언스 주식회사 피브로넥틴 단편 및 면역글로불린 단편의 융합 단백질 및 이의 용도
WO2012137479A1 (ja) * 2011-04-04 2012-10-11 国立大学法人東京医科歯科大学 Ｈｉｖ立体構造認識抗体誘導ペプチド
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
RU2739209C2 (ru) 2011-06-10 2020-12-21 Ханми Сайенс Ко., Лтд. Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения
TR201901402T4 (tr) * 2011-06-17 2019-02-21 Hanmi Science Co Ltd Oksintomodulin ve bir immünoglobulin fragmanı içeren bir konjugat ve onun kullanımı.
RU2622077C2 (ru) * 2011-09-05 2017-06-09 Ханми Сайенс Ко., Лтд. Фармацевтическая композиция для лечения рака, содержащая конъюгат интерферона-альфа
JP6108630B2 (ja) * 2011-10-06 2017-04-05 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅ Ｃｏ．，Ｌｔｄ． 血液凝固因子ＶＩＩ及びＶＩＩａ誘導体、それらを含む結合体及び複合体、並びにそれらの使用
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
AR090281A1 (es) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
US10064951B2 (en) * 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
CN103509118B (zh) * 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
WO2014013262A1 (en) * 2012-07-19 2014-01-23 Oxford Nanopore Technologies Limited Enzyme construct
US10441665B2 (en) * 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
WO2014073842A1 (en) * 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
AR096891A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
CN105848645A (zh) * 2013-09-27 2016-08-10 韩美药品株式会社 持续型人生长激素制剂
DK3127923T3 (da) 2014-03-31 2021-11-22 Hanmi Pharm Ind Co Ltd Fremgangsmåde til forbedring af oppløselighed af protein og peptid ved hjælp af immunoglobulin-fc-fragment-binding
AR100695A1 (es) * 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
CA3010265A1 (en) * 2015-12-31 2017-07-06 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
CA3029518A1 (en) * 2016-06-29 2018-01-04 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof

Also Published As

Publication number Publication date
SG10202107752PA (en) 2021-09-29
IL248111B (en) 2022-04-01
JP2017511335A (ja) 2017-04-20
EA201691795A1 (ru) 2017-03-31
HUP1600621A2 (en) 2017-01-30
UA124182C2 (uk) 2021-08-04
CA2944138A1 (en) 2015-10-08
MY192248A (en) 2022-08-10
MX2016012788A (es) 2016-12-12
EP3889185A2 (en) 2021-10-06
KR20220042326A (ko) 2022-04-05
HU231358B1 (hu) 2023-03-28
JP7333249B2 (ja) 2023-08-24
ES2897935T3 (es) 2022-03-03
AU2015242657B2 (en) 2020-05-21
NZ724926A (en) 2023-11-24
AU2015242657A1 (en) 2016-10-27
KR20150113934A (ko) 2015-10-08
EP3127923B1 (en) 2021-08-18
CN117065044A (zh) 2023-11-17
EP3127923A1 (en) 2017-02-08
WO2015152618A1 (ko) 2015-10-08
EP3889185A3 (en) 2022-01-26
JP2021167352A (ja) 2021-10-21
CN106488933A (zh) 2017-03-08
NO20161667A1 (en) 2016-10-19
SG11201608120TA (en) 2016-11-29
CA2944138C (en) 2023-06-20
IL248111A0 (en) 2016-11-30
DK3127923T3 (da) 2021-11-22
US20230220034A1 (en) 2023-07-13
KR102385120B1 (ko) 2022-04-12
PH12016501937A1 (en) 2017-02-06
JP2020040983A (ja) 2020-03-19
ZA201607344B (en) 2019-04-24
US20170128589A1 (en) 2017-05-11
JP7322105B2 (ja) 2023-08-07
EP3127923A4 (en) 2018-04-18
PL3127923T3 (pl) 2022-01-31

Similar Documents

Publication Publication Date Title
BR112016022844A2 (pt) método para aperfeiçoar a solubilidade de proteínas e peptídeos utilizando-se uma ligação de fragmento fc de imunoglobulinas
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
BR112016024780A2 (pt) composições e métodos relacionados com construtos de fc manipulados
DOP2018000181A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201691974A1 (ru) Антитела против ox40 и способы их применения
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
EA201690314A1 (ru) Анти-garp-белок и его применения
EA201692437A1 (ru) Комбинация
CL2018000249A1 (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
EA201591661A1 (ru) Пептиды и композиции для лечения повреждений суставов
BR112017012381A2 (pt) imunoterapia para doença angiogênica
EA202090683A3 (ru) Способы и композиции для лечения рака
EA201591931A1 (ru) Композиции оксабициклогептанов и оксабициклогептенов
BR112018012388A2 (pt) imunoglobulinas conjugadas de lisina terminal-c
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
DOP2017000260A (es) Piroglutamato de vortioxetina
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/03/2015, OBSERVADAS AS CONDICOES LEGAIS